Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

77results about How to "Does not cause immune rejection" patented technology

Cardiac muscle tonifying tablet taking acellular biological membrane as carrier as well as preparation method and application of cardiac muscle tonifying tablet

ActiveCN104436305AHelps maintain sterilityImprove decellularization efficiencyProsthesisCross-linkNutrition support
The invention discloses a cardiac muscle tonifying tablet taking an acellular biological membrane as a carrier as well as a preparation method and application of the cardiac muscle tonifying tablet. The cardiac muscle tonifying tablet taking the acellular biological membrane as the carrier is prepared by the following steps: carrying out decellularizing treatment on a natural biological membrane; then, cross-linking nutrient substances on the acellular biological membrane; planting target cells on the acellular biological membrane cross-linked with the nutrient substances; and cultivating a cell sheet which is preliminarily constructed, so that the cardiac muscle tonifying tablet taking the acellular biological membrane as the carrier is prepared. The cardiac muscle tonifying tablet disclosed by the invention is good in proliferation and differentiation activities and mechanical strength, and is sufficient in nutrition support; the cardiac muscle tonifying tablet is not only a breakthrough in tissue engineering but also suitable for the clinical treatment of myocardial infarction. The cardiac muscle tonifying tablet disclosed by the invention is reliable in principle, good in reproducibility, and suitable for standard production.
Owner:JINAN UNIVERSITY

Biological amnion and preparation method thereof

The invention relates to a biological amnion and a preparation method thereof. The biological amnion has three layers including a slow release layer, an amnion layer and a collagen layer from top to bottom, wherein the slow release layer consists of collagen and biological active factors, the amnion layer consists of an amnion subjected to decellularization treatment, and the collagen layer is formed by freeze-drying and compounding collagen. The biological amnion is prepared through the steps of raw material pretreatment, virus inactivation, decellularization treatm. The biological amnion prepared by the invention has the characteristics of an effect of slowly releasing the active factors, low antigenicity on removing epithelial cells, convenience in product operation, difficulty in curling, good adhesiveness with surrounding tissues, difficulty in sliding and the like. Meanwhile, by using a process for performing the decellularization treatment on the amnion, disclosed by the invention, a natural compact collagen structure in the amnion can be effectively retained, the biological amnion can fully achieve a physical barrier effect after being applied to tenorrhaphy, and an animal experiment proves that the biological amnion can effectively achieve an effect of preventing tissue adhesion.
Owner:SHAANXI RUISHENG BIOTECH

Method for preparing ACE (Angiotensin Converting Enzyme) inhibitory peptides through compound enzymatic hydrolysis of feta protein

The invention provides a method for preparing ACE (Angiotensin Converting Enzyme) inhibitory peptides through compound enzymatic hydrolysis of feta protein. The method comprises the following steps of: centrifuging and degreasing recovered goat milk taken as a raw material, preparing casein by an isoelectric precipitation method, carrying out compound hydrolysis on the casein through neutral protease and trypsase under the conditions of specific temperature and pH, optimizing the hydrolysis condition, treating the hydrolytic process with ultrasound waves to obtain small-molecule ACE inhibitory peptides and determining the activity of the small-molecule ACE inhibitory peptides. The inhibitory proportion of an ACE inhibitory peptide product prepared by the method can reach above 80%; the ACE inhibitory peptide product has small molecular mass, can be absorbed by a human body in the form of complete peptide fragments and cannot cause the immunological rejection of the human body; and the ACE inhibitory peptide product has an obvious antihypertensive effect on hypertensive, has no effect on people with normal blood pressure and has the characteristics of little dosage, no toxic or side effect, mild property and strong physiological function.
Owner:SHAANXI UNIV OF SCI & TECH

Polyvinyl alcohol hydrogel, method for preparing same and application of polyvinyl alcohol hydrogel

The invention relates to polyvinyl alcohol hydrogel, a method for preparing the same and application of the polyvinyl alcohol hydrogel, and belongs to the field of polymeric hydrogel. The method for preparing the polyvinyl alcohol hydrogel includes heating and dissolving polyvinyl alcohol and organic solvents at the temperature of 110-145 DEG C to obtain polyvinyl alcohol solution; allowing the obtained polyvinyl alcohol solution to stand still to naturally cool the polyvinyl alcohol solution until the temperature of the polyvinyl alcohol solution reaches the room temperature so as to obtain polyvinyl alcohol with gel structures; removing the organic solvents from the polyvinyl alcohol with the gel structures to obtain the polyvinyl alcohol hydrogel. The organic solvents are blended solvents with dimethyl sulfoxide and N-N, dimethylformamide, and a volume ratio of the dimethyl sulfoxide to the N-N, dimethylformamide is 0.25-1; the mass concentration of the obtained polyvinyl alcohol solution is 10-30%. The polyvinyl alcohol hydrogel, the method and the application have the advantages that an appropriate proportion of solvents are applied when the polyvinyl alcohol solution is prepared, and accordingly the polyvinyl alcohol hydrogel can be prepared from the obtained polyvinyl alcohol solution in standing and natural cooling modes.
Owner:ZHENGZHOU UNIV

Preparation method of lymphoma-targeted blood platelet targeting drug loading system carrying and loading anti-tumor drug and connecting CD22 monoclonal antibody

The invention discloses a preparation method of a lymphoma-targeted blood platelet targeting drug loading system which carries and loads a CD22 monoclonal antibody and an anti-tumor drug. The preparation method comprises the following steps: firstly deeply centrifuging and washing blood platelet-enriched blood plasma obtained through whole blood anticoagulation and centrifugation, obtaining washed blood platelets, treating a maleimide group with the surface modified with a pointing sulfhydryl by adopting an MBS reagent, and then reacting with an anti-CD22 monoclonal antibody subjected to sulfhydrylation by virtue of a Traut's reagent, so that the blood platelets which connect the CD22 monoclonal antibody and target lymphoma cells are obtained; and then carrying out mixed incubation on the blood platelets and the anti-tumor drug, centrifuging, and dispersing, so that the target drug loading system is obtained finally. The drug loading system has the advantages of wide source, high drug loading ratio, good biocompatibility, active and accurate targeting, long cycling time and the like, the anti-tumor effect of the drug can be enhanced, and the toxicity on normal tissues is also reduced, so that toxic and side effects of a chemotherapy drug are alleviated, and the drug loading system is significant for improving the life quality and medical quality of a patient with lymphoma.
Owner:NANJING DRUM TOWER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products